GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer
Shots:
- The EC has approved Jemperli + CT (carboplatin & paclitaxel) as a 1L treatment of primary advanced or recurrent endometrial cancer in adults eligible for systemic therapy
- Approval was based on part 1 of P-III (RUBY) study assessing Jemperli + CT followed by Jemperli vs CT + PBO followed by PBO and part 2 evaluating Jemperli + CT followed by Jemperli + niraparib vs PBO in patients (n=785) with primary advanced/recurrent endometrial cancer
- Part 1 of the trial showed a 31% reduction in death risk among full population. At 2.5yrs., 61% of patients on Jemperli were alive vs 49% on chemotherapy alone, with a 16.4mos. improvement in mOS (44.6 vs 28.2mos.)
Ref: GSK | Image: GSK
Related News:- GSK’s GSK’227 Secures the US FDA’s Breakthrough Therapy Designation for Treating Late-Line R/R Osteosarcoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
